CN112617191B - 一种改善糖代谢的药食同源组合物及其制备方法 - Google Patents
一种改善糖代谢的药食同源组合物及其制备方法 Download PDFInfo
- Publication number
- CN112617191B CN112617191B CN202011506079.7A CN202011506079A CN112617191B CN 112617191 B CN112617191 B CN 112617191B CN 202011506079 A CN202011506079 A CN 202011506079A CN 112617191 B CN112617191 B CN 112617191B
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- medicine
- food
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000023852 carbohydrate metabolic process Effects 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 49
- 240000005979 Hordeum vulgare Species 0.000 claims abstract description 20
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 20
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 17
- 230000004060 metabolic process Effects 0.000 claims abstract description 17
- 240000006162 Chenopodium quinoa Species 0.000 claims abstract description 16
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 16
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 16
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 16
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 15
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 14
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 12
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 11
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 11
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 240000008620 Fagopyrum esculentum Species 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 64
- 235000013339 cereals Nutrition 0.000 claims description 25
- 230000001954 sterilising effect Effects 0.000 claims description 22
- 238000007873 sieving Methods 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 17
- 210000000582 semen Anatomy 0.000 claims description 15
- 239000011812 mixed powder Substances 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 14
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- 238000007605 air drying Methods 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 7
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 60
- 235000013305 food Nutrition 0.000 abstract description 42
- 210000004369 blood Anatomy 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 27
- 210000003734 kidney Anatomy 0.000 abstract description 22
- 210000000952 spleen Anatomy 0.000 abstract description 21
- 210000004185 liver Anatomy 0.000 abstract description 18
- 235000016709 nutrition Nutrition 0.000 abstract description 13
- 239000000463 material Substances 0.000 abstract description 10
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 4
- 229930186217 Glycolipid Natural products 0.000 abstract description 4
- 230000033228 biological regulation Effects 0.000 abstract description 4
- 230000001603 reducing effect Effects 0.000 abstract description 4
- 210000001835 viscera Anatomy 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 29
- 230000000694 effects Effects 0.000 description 19
- 235000012054 meals Nutrition 0.000 description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 238000011160 research Methods 0.000 description 13
- 241000219051 Fagopyrum Species 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 8
- 235000017784 Mespilus germanica Nutrition 0.000 description 7
- 244000182216 Mimusops elengi Species 0.000 description 7
- 235000000560 Mimusops elengi Nutrition 0.000 description 7
- 235000007837 Vangueria infausta Nutrition 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 235000013325 dietary fiber Nutrition 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000020828 fasting Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000307676 Diploprion bifasciatum Species 0.000 description 2
- 244000130270 Fagopyrum tataricum Species 0.000 description 2
- 235000014693 Fagopyrum tataricum Nutrition 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000020927 12-h fasting Nutrition 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 235000015493 Chenopodium quinoa Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010052097 Dawn phenomenon Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013228 adult male C57BL/6J mice Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/20—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof consisting of whole seeds or seed fragments
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明实施例公开了一种改善糖代谢的药食同源组合物及其制备方法,属于食品技术领域。一种改善糖代谢的药食同源组合物,包括以下重量份数的原料:生山药10‑30份、黄精5‑25份、枸杞子5‑20份、藜麦7‑25份、荞麦10‑30份、薏苡仁5‑30份、青稞5‑30份。本发明以中医脏腑相关理论及药食同源理论为指导,所选的原料均是药食同源食材,多归经于肝脾肾三脏,在肝脾肾三脏同调原则指导下配伍而成。同时兼顾现代营养学及药理学观点,既考虑到糖尿病患者代谢的营养需求,又发挥了所选食材所含组分的降糖功效。通过多层次、多靶位、多角度的协同作用,达到调节糖脂代谢的目的。
Description
技术领域
本发明实施例涉及食品技术领域,具体涉及一种改善糖代谢的药食同源组合物及其制备方法。
背景技术
糖尿病是多种因素引起胰岛素分泌绝对或相对不足,引起血糖升高的一种代谢紊乱性疾病。糖尿病的高致死率、高致残率和治疗糖尿病及其并发症的高额费用给患者、家庭和社会造成了沉重的经济负担。2019年国际糖尿病联盟发布最新数据,目前全球有4.63亿糖尿病患者,按照增长趋势到2045年全球将有7亿糖尿病患者。糖尿病对我国居民身体健康构成了严重威胁,严重者出现冠心病、脑血管疾病和周围血管病变等大血管并发症。此外,糖尿病患者罹患心血管疾病风险增加2-4倍,接近一半的2型糖尿病患者将死于心血管疾病,是主要并发症及致死病因,且糖尿病患者高血压患病率和中风发生率均为非糖尿病患者的2倍,甚者出现感染、溃疡和截肢的严重且治疗昂贵的并发症,因此糖尿病的防治迫在眉睫。
在糖尿病防治中,饮食疗法是贯穿始终的最重要的手段。在饮食干预中,主食干预是一种重要的手段。中医治疗糖尿病独具特色,尤其是运用饮食调养和药膳来治疗消渴病更是中医学的优势疗法。将中医“治未病”思想以及“药食同源”理论运用到糖尿病的防治上,是延缓糖尿病发生发展的重要途径。运用兼具营养和治疗作用的药食两用的食材,制作成功能食品防治糖尿病具有十分重要的意义。
不同饮食结构对糖尿病的发生发展及预后有不同的影响,饮食是糖尿病防控中重要环节。许多糖尿病患者认为主食就是碳水化合物,不能多吃,减少主食的量就可以降低血糖,更有甚者,只吃青菜,不吃主食。但是,此举之下,糖尿病患者的血糖并没有得到良好的控制,反而易于出现低血糖、反应性高血糖、酮症酸中毒、恶性糖异生等不良后果。诸多医者临床实践表明,适当进食谷类主食反而利于糖尿病的治疗及维持血糖的正常化,尤其是全谷物,富含膳食纤维,不仅为机体提供营养,还可调节糖脂代谢,改善肠道内环境。《素问·藏气法时论篇》言:“毒药攻邪,五谷为养,五果为助,五畜为益,五菜为充,气味合而服之,以补精益气”。这充分强调了五谷类主食对人体的重要作用,对正常人和糖尿病患者都应被奉为不可违越的饮食之道。
目前市面上的谷物类降糖食品,多是依据其含糖量的偏低及所含成分可能具有的某种相关效应而进行的谷物的复合,或添加药食同源中的某些具有相关效应药物,由于没能抓住糖尿病的基本病机,故有效的产品凤毛麟角。
为此,本发明实施例提供一种在中医理论指导下的改善糖代谢的药食同源组合物及其制备方法,以解决现有技术中由于作用靶点不明确而导致的效果不佳的问题。
发明内容
本发明是以前期研究基础“糖尿病肝脾肾三脏同调理论”为指导,抓住了糖尿病的基本病机。具体指导理论内容如下:
现代医学认为糖尿病的基本病变为三大营养物质代谢紊乱,而糖、脂肪、蛋白质等物质按中医认识皆属于水谷之精微,靠脾的运化而布散全身,这些物质不能正常代谢,应责之于脾的运化失职。情志刺激、压力、焦虑等因素是糖尿病的重要诱因,糖尿病自始至终均存在血液的高凝状态,糖尿病的黎明现象恰巧作于中医肝气当令的平旦之时,糖尿病尤易出现视物昏花的目疾和头晕上逆的高血压等也均证明了糖尿病不离乎中医的肝。糖尿病的发病具有遗传易感性,且发病率随着年龄的增长而升高,到60岁达到高峰,中医认为肾主生殖,故与遗传相关的疾病大多与肾相关;60岁后为肝肾虚衰的年龄阶段,此时发生的疾病亦多是因肝肾虚衰所导致;糖尿病的典型症状是有糖自小便排出,从中医的角度也当责之于肾的固摄失司。凡此皆证明糖尿病的病理生理与中医的肝、脾、肾三脏的病理生理是密切相关的。因此,糖尿病的中医病机是肝、脾、肾三脏同病,其防治应立足肝脾肾,三脏同调。在该理论指导下我们团队进行了一系列基础与临床研究,其研究成果先后获得省部级一等奖1项、二等奖1项、国家科技进步二等奖1项。
本发明以中医脏腑相关理论及药食同源理论为指导,所选的原料均是药食同源食材,多归经于肝脾肾三脏,在肝脾肾三脏同调原则指导下配伍而成。同时兼顾现代营养学及药理学观点,既考虑到糖尿病患者代谢的营养需求,又发挥了所选食材所含组份的降糖功效。
为了实现上述目的,本发明实施例提供如下技术方案:
根据本发明实施例的第一方面,本发明实施例提供一种改善糖代谢的药食同源组合物,包括以下重量份数的原料:生山药10-30份、黄精5-25份、枸杞子5-20份、藜麦7-25份、荞麦10-30份、薏苡仁5-30份、青稞5-30份。
进一步地,包括以下重量份数的原料:生山药20份、黄精10份、枸杞子5份、藜麦15份、荞麦20份、薏苡仁10份、青稞20份。
根据本发明实施例的第二方面,本发明实施例提供一种上述的改善糖代谢的药食同源组合物的制备方法,包括以下步骤:
按照配比称取各成分;藜麦、荞麦、薏苡仁和青稞用文火炒制成熟料,粉碎成细粉,过筛,得到谷物粉末;生山药、黄精、枸杞子干燥,粉碎成细粉,过筛,得到中药粉末;将谷物粉末和中药粉末均匀,杀菌、包装即得。
进一步地,包括以下步骤:
1)按照配比称取各成分;
2)藜麦、荞麦、薏苡仁和青稞,去除杂质,清洗风干后,放入铁锅内,文火炒制20-30min,得到熟料,用破壁机粉碎成细粉,过60-80目筛,得到谷物粉末;
3)使用果蔬烘干机对生山药、黄精和枸杞子进行烘干,然后用破壁机粉碎成细粉,过60-80目筛,得到中药粉末;
4)步骤2)的谷物粉末和步骤3)的中药粉末放入搅拌机内,搅拌混匀,得到混合粉末;
5)步骤4)的混合粉末置于微波杀菌设备进行杀菌,分装,即得。
进一步地,步骤2)中,所述破壁机的转速为3000-5000r/min,粉碎时间为15-30分钟。
进一步地,步骤3)中,所述烘干机的温度为120-130℃,烘干时间为30-40min,所述破壁机的转速为3000-5000r/min,粉碎时间为15-30分钟。
进一步地,步骤4)中,所述搅拌机以500-800r/min的速度搅拌15-30分钟。
进一步地,步骤5)中,所述微波杀菌设备的杀菌温度为100-110℃,杀菌时间为3-5分钟。
具体原料分析如下:
“药食同源”是饮食养生中的基本原则,在《黄帝内经大素》中写到“空腹食之为食物,患者食之为药物”,《素问·五常政大论篇第七十》等也论述过“以食代药”、“药补不如食补”,这些都说明食物和药物同样都有疗病作用,二者同源,并且《黄帝内经》中还写到药物和食物都一样,有“寒、热、温、凉”之性和“酸、苦、甘、辛、咸”之味。
山药:性甘,平;归脾、肺、肾经,具有补脾养胃、生津益肺、补肾涩精之功。山药块茎中主要含有淀粉、蛋白质、游离氨基酸、钙、铁、磷等营养成分和一些微量元素,以及多糖、黄酮、皂苷等多种活性成分,这些化学成分形成了山药营养价值和活性作用,是利用山药的物质基础,诸多研究表明山药多糖、新鲜山药中薯蓣皂苷等可能通过增加胰岛素的敏感性而降低血糖。
枸杞子:性甘,平;归肝、肾经,具有滋补肝肾,益精明目之功。枸杞子的营养十分丰富,每100克中含有蛋白质4克、脂肪0.8克、糖类19.3克、钙55毫克、磷86毫克、胡萝卜素8.6毫克,以及各种维生素。研究结果表明,枸杞总黄酮提取物对2型糖尿病大鼠可延缓其血糖升高速度,调节血脂代谢的紊乱,可明显保护糖尿病大鼠的胰岛功能,进而起到改善大鼠的胰岛素抵抗的作用。
黄精:味甘,性平;归脾、肺、肾经,具有养阴润肺,补脾益气,滋肾填精之功。黄精在医学界一直被列为是延年益寿的珍贵中药之一。研究结果表明黄精多糖能改善链脲佐菌素(STZ)诱导的糖尿病大鼠症状,降低血糖、血脂水平和血清糖化血红蛋白浓度,增强胰岛素敏感性,改善糖尿病大鼠脂代谢紊乱及胰岛素抵抗。
藜麦:归脾、胃经,具有健脾益胃、清化痰湿的作用。联合国粮农组织认为藜麦是唯一一种可满足人体基本营养需求的单体植物,被国际营养学家称为“营养黄金”、“超级谷物”和“未来食品”。不仅富含蛋白质及钙、铁、锌、维生素E等微量营养素和全部的必需氨基酸,还具有提高人群营养水平和预防多种疾病的功能成分;而且具有高蛋白、高纤维、高维生素、低脂,低热量,低血糖指数,矿物质含量极为丰富。膳食纤维能延长食物在胃中停留时间,减慢消化道中葡萄糖被肠壁吸收的速度,使餐后血糖上升缓慢,有利于糖尿病的缓解。研究发现藜麦主要成分20-羟基蜕皮酮可以有效降低血糖和体重;可通过调节肥胖糖尿病小鼠粪便微生物生态,降低盲肠中丁酸及琥珀酸浓度以改善糖尿病;长期食用藜麦淀粉能有效控制血糖、有效抑制餐后血糖的快速上升及改善胰岛素抵抗。
荞麦:性凉、味甘;归脾经、胃经、大肠经,具有宽肠下气、清热解毒、消积开胃、补虚敛汗等功效。据《本草纲目》记载:荞麦“降气宽肠、磨积滞、消热肿风痛、除白浊白带、脾积泄泻”。现代药理学研究发现苦荞含有丰富的膳食纤维、蛋白质、维生素、微量元素等。荞麦是唯一含有芦丁的粮食作物,它能使毛细血管的结合部位变得柔韧,有弹性,荞麦中的胆碱有防止大脑细胞氧化、防止记忆力减退、老年痴呆等功效,其含有的黄酮成分,可起到抗菌、消炎、止咳、平喘、祛痰的作用。诸多研究亦发现荞麦及其提取物具有降糖之效。
青稞:性平、味咸;具有补脾、养胃、益气、止泻、强筋力之功效。据《本草纲目拾遗》记载:“青稞下气宽中、壮筋益力、除湿发汗、止泄。”青稞是大麦的变种,俗称裸大麦,青稞各种营养成分与普通大麦相似,但β-葡聚糖远高于普通大麦。β-葡聚糖能够调节血糖代谢、降低胆固醇、增强免疫力。
薏苡仁:性凉、味甘、淡;归脾、胃、肺经,具有利水消肿、健脾去湿、舒筋除痹、清热排脓之功。研究表明,薏苡仁提取物薏苡仁多糖具有抗氧化功效,对胰岛β细胞有保护作用,避免自由基对其损伤和血清脂质过氧化状况得到抑制。薏苡仁多糖亦可提升人体葡萄糖激酶活性,对葡萄糖利用有促进作用,使糖脂代谢紊乱和胰岛素抵抗得到一定改善。
本发明实施例具有如下优点:
1、本发明的药食同源组合物以生山药、黄精、枸杞子、藜麦、荞麦、薏苡仁、青稞为原料制成,既能调节肝脾肾功能,又富含膳食纤维、蛋白质、氨基酸、矿物质、维生素等,通过多层次、多靶位、多角度的协同作用,达到调节糖脂代谢的目的。
2、本发明的药食同源糖尿病代餐食品,从中医学消渴病的病因病机结合现代医学对糖尿病病理生理的认识,以“糖尿病肝脾肾三脏同调理论”为指导,且在理论指导下进行过一系列临床与基础研究,研究成果获得国家科学技术二等奖以及省部级一等奖和二等奖。本配方选取具有相应治疗作用的药食两用的药材和营养丰富、富含膳食纤维、蛋白质、氨基酸、维生素等营养物质的食材精致而成,有利于从根本上控制糖尿病病情的发展。
3、本发明根据“糖尿病肝脾肾三脏同病”的病机特点,结合中医食疗理论以及现代营养学观点,选择药食两用的生山药、枸杞子、黄精,以及富含膳食纤维和微量元素的营养谷物高原藜麦、高原青稞、生态苦荞、生态薏苡仁,利用先进工艺,精制成一种肝脾肾三脏同调的功能性糖尿病代餐主食粉,还可以作为营养强化粉,添加到传统食品,如面条、面包、馒头、饼干、复合米中,纯天然无添加且食用方便。不仅具有低热量、高蛋白、多营养的特点,还兼具辅助调节血糖之效。可供糖尿病人群当做主食食用,亦可作为健康人平素的养生保健食品,有较高的社会价值和经济价值,易于推广。
具体实施方式
以下由特定的具体实施例说明本发明的实施方式,熟悉此技术的人士可由本说明书所揭露的内容轻易地了解本发明的其他优点及功效,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种改善糖代谢的药食同源组合物的制备方法包括以下步骤:
1)取藜麦15份、荞麦20份、薏苡仁10份、青稞20份,去除杂质,清洗风干后,放入铁锅内,文火炒制30min,得到熟料,再将得到的熟料放入破壁机内,以5000r/min的转速粉碎20分钟,过80目筛,制得谷物粉末,备用;
2)取生山药20份、黄精10份、枸杞子5份放入果蔬烘干机内,控制烘干机的烘干温度为120℃,烘干时间为40min,然后放入破壁机内,以3000r/min的速度粉碎15分钟,过60目筛,制得中药粉末,备用;
3)步骤1)的谷物粉末和步骤2)的中药粉末放入搅拌机内,以600r/min的速度搅拌30分钟,得到混合粉末,备用;
4)将步骤3)的混合粉末置于微波杀菌设备内,在100℃的条件下,杀菌3分钟,再将杀菌后的粉末分袋包装,即可。
实施例2
一种改善糖代谢的药食同源组合物的制备方法包括以下步骤:
1)取藜麦10份、荞麦30份、薏苡仁15份、青稞15份,去除杂质,清洗风干后,放入铁锅内,文火炒制30min,得到熟料,再将得到的熟料放入破壁机内,以5000r/min的转速粉碎20分钟,过80目筛,制得谷物粉末,备用;
2)取生山药30份、黄精10份、枸杞子20份放入果蔬烘干机内,控制烘干机的烘干温度为120℃,烘干时间为40min,然后放入破壁机内,以3000r/min的速度粉碎15分钟,过60目筛,制得中药粉末,备用;
3)步骤1)的谷物粉末和步骤2)的中药粉末放入搅拌机内,以600r/min的速度搅拌30分钟,得到混合粉末,备用;
4)将步骤3)的混合粉末置于微波杀菌设备内,在100℃的条件下,杀菌3分钟,再将杀菌后的粉末分袋包装,即可。
实施例3
一种改善糖代谢的药食同源组合物的制备方法包括以下步骤:
1)取藜麦25份、荞麦10份、薏苡仁20份、青稞30份,去除杂质,清洗风干后,放入铁锅内,文火炒制30min,得到熟料,再将得到的熟料放入破壁机内,以5000r/min的转速粉碎20分钟,过80目筛,制得谷物粉末,备用;
2)取生山药25份、黄精15份、枸杞子15份放入果蔬烘干机内,控制烘干机的烘干温度为120℃,烘干时间为40min,然后放入破壁机内,以3000r/min的速度粉碎15分钟,过60目筛,制得中药粉末,备用;
3)步骤1)的谷物粉末和步骤2)的中药粉末放入搅拌机内,以600r/min的速度搅拌30分钟,得到混合粉末,备用;
4)将步骤3)的混合粉末置于微波杀菌设备内,在100℃的条件下,杀菌3分钟,再将杀菌后的粉末分袋包装,即可。
实施例4
一种改善糖代谢的药食同源组合物的制备方法包括以下步骤:
1)取藜麦7份、荞麦15份、薏苡仁30份、青稞5份,去除杂质,清洗风干后,放入铁锅内,文火炒制30min,得到熟料,再将得到的熟料放入破壁机内,以5000r/min的转速粉碎20分钟,过80目筛,制得谷物粉末,备用;
2)取生山药30份、黄精20份、枸杞子20份放入果蔬烘干机内,控制烘干机的烘干温度为120℃,烘干时间为40min,然后放入破壁机内,以3000r/min的速度粉碎15分钟,过60目筛,制得中药粉末,备用;
3)步骤1)的谷物粉末和步骤2)的中药粉末放入搅拌机内,以600r/min的速度搅拌30分钟,得到混合粉末,备用;
4)将步骤3)的混合粉末置于微波杀菌设备内,在100℃的条件下,杀菌3分钟,再将杀菌后的粉末分袋包装,即可。
实施例5
一种改善糖代谢的药食同源组合物的制备方法包括以下步骤:
1)取藜麦20份、荞麦25份、薏苡仁25份、青稞10份,去除杂质,清洗风干后,放入铁锅内,文火炒制30min,得到熟料,再将得到的熟料放入破壁机内,以5000r/min的转速粉碎20分钟,过80目筛,制得谷物粉末,备用;
2)取生山药20份、黄精25份、枸杞子5份放入果蔬烘干机内,控制烘干机的烘干温度为120℃,烘干时间为40min,然后放入破壁机内,以3000r/min的速度粉碎15分钟,过60目筛,制得中药粉末,备用;
3)步骤1)的谷物粉末和步骤2)的中药粉末放入搅拌机内,以600r/min的速度搅拌30分钟,得到混合粉末,备用;
4)将步骤3)的混合粉末置于微波杀菌设备内,在100℃的条件下,杀菌3分钟,再将杀菌后的粉末分袋包装,即可。
测试例
为了说明本发明实施例的药食同源组合物能够有效改善糖代谢,本发明进行了如下实验:
1材料与方法
1.1饲料与药物制备
用蒸馏水将实施例1的组合物和至面团状,制备成与普通动物饲料形状及大小相似的圆柱形颗粒食物(直径约12mm,高约30mm),微波炉烤220℃烤2分钟,晾干备用。普通饲料及高脂饲料(重量配方:20%蔗糖、2.5%胆固醇、10%猪油、1%胆酸钠、66.5%基础饲料),购于北京华阜康生物科技股份有限公司。盐酸二甲双胍片(中美上海施贵宝有限公司,批号1005023)。
1.2动物
SPF级成年雄性C57BL/6J小鼠,体质量为20±2g,购于北京斯贝福实验动物有限公司,许可证号SCXK(京)2008-0002。饲养于北京中医药大学屏障环境动物实验室,合格证号SCXK(京)2011-0024,室温20℃,相对湿度45%左右,光暗周期(12h/12h)。
1.3仪器和试剂
全自动生化分析仪(深圳迈瑞生物医疗电子股份有限公司);拜安康快速血糖仪、一次性血糖试纸、iMark标仪(美国Bio-rad公司);高速离心机(5424型,德国Eppendorf);电子分析天平(AX120,日本岛津)等。
链脲佐菌素(美国Sigma公司);胰岛素试剂盒(天津盛达生物科技有限公司);甘油三酯、总胆固醇、低密度脂蛋白、高密度脂蛋白试剂盒(南京建成生物工程研究所)。
1.4方法
1.4.1动物模型的制备:C57BL/6J雄性小鼠40只,适应性饲养1周,随机抽取6只作为正常组,普通饲料喂养;其余24只小鼠采用高脂饲料喂养4周后,高脂饲料喂养组禁食12h,链脲佐菌素(STZ)按120mg/kg腹腔注射小鼠。普通饲料喂养组同期注射同体积的柠檬酸-柠檬酸钠缓冲液。3d后检测禁食12h后血糖,以空腹血糖>11.1mmol/L为糖尿病造模成功标准,成模率75%,即18只小鼠血糖符合糖尿病模型标准。MiniQMR动物体脂定量分析仪检测小鼠体内脂肪及瘦肉的水平。
1.4.2分组与给药方法:按血糖将符合糖尿病造模要求的小鼠18只随机分组,其中模型组6只,阳性药物组6只,代餐粉组6只。代餐粉组给予实施例1的药食同源组合物制成的代餐粉饲料自由喂食;正常组给予普通饲料自由喂食;模型组和阳药组继续给予高脂饲料自由喂食,阳性药物组给予二甲双胍,给药量为0.15g/kg。共喂养8周。
1.4.3标本采集与指标检测:小鼠眼球取血,留取血清检测空腹血糖(FBG)、空腹胰岛素(FINS)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)。
1.5统计学处理
采用SPSS 22.0对实验数据进行统计分析,计量资料用x±s表示,前后比较采用配对t检验,组间比较采用单因素方差分析,两两比较采用LSD法,P<0.05认为差异有统计学意义。
2结果
2.1各组小鼠体重变化
表1各组小鼠造模后体重、干预后体重比较(x±s)
*P<0.05,与正常组比较;△P<0.05,与模型组比较。
表1结果显示,造模成功后,与正常组比,模型组体重下降,符合糖尿病体重减轻的表现;干预8周后,二甲双胍组、代餐粉组体重较模型组明显升高,差异有统计学意义。提示二甲双胍、药食同源代餐粉可改善糖尿病小鼠的消瘦状态,起到增长体重的作用。
2.2各组小鼠体脂变化
表2各组小鼠干预前体脂、干预后体脂比较(x±s)
*P<0.05,与正常组比较;△P<0.05,与模型组比较。
表2结果显示,造模成功后(即干预前),与正常组比,模型组小鼠身体脂肪含量明显高于正常;干预8周后,二甲双胍及代餐粉组小鼠身体脂肪含量较模型组明显下降,说明药食同源代餐粉可降低糖尿病小鼠体脂的含量。
2.3各组小鼠FBG、FINS水平比较
表3各组小鼠干预前FBG、干预后FBG水平比较(x±s)
*P<0.05,与正常组比较;△P<0.05,与模型组比较。
表3结果显示,干预前后,与正常组比较,模型组小鼠血清FBG水平均明显升高,差异均有统计学意义(P<0.05),说明造模成功;与模型组比较,代餐粉组、二甲双胍组小鼠血清FBG水平明显降低,差异均有统计学意义(P<0.05)。提示药食同源代餐粉可降低2型糖尿病小鼠空腹血糖。
2.4各组小鼠FINS水平比较
表4各组小鼠FINS水平比较(x±s)
*P<0.05,与正常组比较;△P<0.05,与模型组比较。
表4结果显示,与正常组比较,模型组血清FINS明显下降,差异有统计学意义,符合2型糖尿病胰岛素分泌减少的病理特征;与模型组比较,代餐粉组、二甲双胍组FINS均升高,差异有统计学意义。提示药食同源代餐粉可促进2型糖尿病小鼠胰岛素分泌,从而调节糖代谢。
2.5各组小鼠血清TC、TG、HDL-C、LDL-C水平比较
表5各组小鼠TC、TG、HDL-C、LDL-C水平比较(x±s,mmol/L)
*P<0.05,与正常组比较;△P<0.05,与模型组比较。
表5结果显示:与正常组比较,模型组小鼠血清TC、TG、LDL-C水平明显升高,HDL-C水平明显降低,差异均有统计学意义(P<0.05);与模型组比较,药食同源代餐粉组、二甲双胍组小鼠血清TC、TG、LDL-C水平明显降低,差异均具有统计学意义(P<0.05),HDL-C水平较模型组有升高趋势,但无统计学意义。提示糖尿病药食同源代餐粉可调节2型糖尿病小鼠脂代谢。
虽然,上文中已经用一般性说明及具体实施例对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (7)
1.一种改善糖代谢的药食同源组合物,其特征在于,由以下重量份数的原料组成:生山药10-30份、黄精5-25份、枸杞子5-20份、藜麦7-25份、荞麦10-30份、薏苡仁5-30份、青稞5-30份;
制备改善糖代谢的药食同源组合物包括以下步骤:
按照配比称取各成分;藜麦、荞麦、薏苡仁和青稞用文火炒制成熟料,粉碎成细粉,过筛,得到谷物粉末;生山药、黄精、枸杞子干燥,粉碎成细粉,过筛,得到中药粉末;将谷物粉末和中药粉末混合均匀,杀菌、包装即得。
2.根据权利要求1所述的改善糖代谢的药食同源组合物,其特征在于,由以下重量份数的原料组成:生山药20份、黄精10份、枸杞子5份、藜麦15份、荞麦20份、薏苡仁10份、青稞20份。
3.根据权利要求1所述的改善糖代谢的药食同源组合物,其特征在于,包括以下步骤:
1)按照配比称取各成分;
2)藜麦、荞麦、薏苡仁和青稞,去除杂质,清洗风干后,放入铁锅内,文火炒制20-30min,得到熟料,用破壁机粉碎成细粉,过60-80目筛,得到谷物粉末;
3)使用果蔬烘干机对生山药、黄精和枸杞子进行烘干,然后用破壁机粉碎成细粉,过60-80目筛,得到中药粉末;
4)步骤2)的谷物粉末和步骤3)的中药粉末放入搅拌机内,搅拌混匀,得到混合粉末;
5)步骤4)的混合粉末置于微波杀菌设备进行杀菌,分装,即得。
4.根据权利要求3所述的改善糖代谢的药食同源组合物,其特征在于,步骤2)中,所述破壁机的转速为3000-5000r/min,粉碎时间为15-30分钟。
5.根据权利要求3所述的改善糖代谢的药食同源组合物,其特征在于,步骤3)中,所述烘干机的烘干温度为120-130℃,烘干时间为30-40min,所述破壁机的转速为3000-5000r/min,粉碎时间为15-30分钟。
6.根据权利要求3所述的改善糖代谢的药食同源组合物,其特征在于,步骤4)中,所述搅拌机以500-800r/min的速度搅拌15-30分钟。
7.根据权利要求3所述的改善糖代谢的药食同源组合物,其特征在于,步骤5)中,所述微波杀菌设备的杀菌温度为100-110℃,杀菌时间为3-5分钟。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011506079.7A CN112617191B (zh) | 2020-12-18 | 2020-12-18 | 一种改善糖代谢的药食同源组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011506079.7A CN112617191B (zh) | 2020-12-18 | 2020-12-18 | 一种改善糖代谢的药食同源组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112617191A CN112617191A (zh) | 2021-04-09 |
CN112617191B true CN112617191B (zh) | 2022-08-23 |
Family
ID=75317269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011506079.7A Active CN112617191B (zh) | 2020-12-18 | 2020-12-18 | 一种改善糖代谢的药食同源组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112617191B (zh) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100714076B1 (ko) * | 2005-07-12 | 2007-05-02 | 강원생물영농조합법인 | 당뇨병 환자를 위한 혼합조성물을 함유하는 건강기능식품 |
CN103027296B (zh) * | 2013-01-06 | 2014-03-26 | 苏州满园春生物技术有限公司 | 一种适宜糖尿病患者的中药药膳配方食品及其用途 |
CN108295211A (zh) * | 2018-03-22 | 2018-07-20 | 季军 | 一种治疗糖尿病的药食同源食品组方及其制备方法 |
CN110200276B (zh) * | 2019-06-27 | 2023-04-07 | 刘东波 | 基于中药营养的组合物 |
CN110771880A (zh) * | 2019-11-08 | 2020-02-11 | 国家半干旱农业工程技术研究中心 | 一种降糖藜麦代餐粉及其制备工艺 |
-
2020
- 2020-12-18 CN CN202011506079.7A patent/CN112617191B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN112617191A (zh) | 2021-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101347193B (zh) | 能够提供均衡营养的复合米及其制作工艺 | |
US20210352948A1 (en) | Composition for treating diabetes based on traditional Chinese medicine nutritional therapy and application thereof | |
CN102406860B (zh) | 预防和治疗糖尿病的组合物、其制备方法及应用 | |
CN103099089B (zh) | 一种降糖、降压、通便减肥、抗疲劳、改善性功能保健品及其生产工艺 | |
CN103504305B (zh) | 一种具有降血糖功能的保健品及其制备方法 | |
CN1742927A (zh) | 枸杞桑椹片及其制备工艺 | |
CN102526478B (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
JP2008174539A (ja) | 紫色の馬鈴薯を使用した肥満患者用の健康機能食品 | |
CN108719984A (zh) | 一种针对痛风人群的代餐营养棒及其制备方法 | |
CN102204649B (zh) | 一种调节及稳定血糖的保健食品及制备方法 | |
CN110367526A (zh) | 一种低糖高纤维营养代餐粉 | |
CN100444746C (zh) | 一种高寒山区作物精制健康食品及其加工工艺 | |
CN108813590A (zh) | 一种适合糖尿病患者的低gi配方食品及其制备方法 | |
CN107951006A (zh) | 一种具有减肥功能的组合物及其制备方法和用途 | |
CN110574862A (zh) | 一种适用于青少年儿童的营养减肥代餐粉及其制备方法 | |
CN109393309A (zh) | 一种低gi燕麦代餐粉及其制作方法 | |
CN112617191B (zh) | 一种改善糖代谢的药食同源组合物及其制备方法 | |
CN103920140B (zh) | 一种人用降糖减肥降脂复方制剂 | |
CN102150779B (zh) | 一种调节及稳定血糖的保健食品及制备方法 | |
CN110638038A (zh) | 一种用于控制高血糖的医学配方营养代餐粉及其制备方法 | |
CN113499366B (zh) | 一种具有同时降低血糖血脂功能的组合物及其制备方法 | |
CN102987402B (zh) | 一种均衡营养的高原天然植物食品及其制备方法 | |
CN109043555A (zh) | 一种高血糖患者食用的特殊食品及其制备方法 | |
CN107616491A (zh) | 一种用于防治糖尿病的功能食品 | |
CN107668703A (zh) | 一种降高血糖的食物组合物及其制造方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |